肿瘤细胞治疗研究
英文原题：Natural killer cell immunotherapy in glioblastoma.
胶质母细胞瘤（GBM）是最难治疗的癌症之一，因为 GBM 具有高度的治疗耐药性。
胶质母细胞瘤（GBM）是最难治疗的癌症之一，因为其治疗耐药性高。近年来，GBM免疫疗法逐步用于替代传统治疗。在各种免疫疗法中，基于自然杀伤（NK）细胞的免疫疗法凭借不受抗原-抗体反应限制以及可深入肿瘤微环境等特性，具有治疗GBM的潜力。尤其是基因工程化NK细胞，如嵌合抗原受体（CAR）NK细胞、双抗原靶向CAR-NK细胞和适配器CAR-NK细胞，被认为是GBM免疫治疗的重要工具。因此，本文综述GBM患者基于NK细胞免疫治疗的近期研究进展，并介绍NK细胞上表达的重要受体，如杀伤细胞免疫球蛋白样受体、CD16和自然杀伤组2成员D（NKG2D）受体，讨论这些分子的功能和重要性。
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments. Among them, Natural killer (NK) cell-based immunotherapy has the potential to treat GBM due to its properties such as the absence of restriction by antigen-antibody reaction and deep penetration into the tumor microenvironment. Especially, genetically engineered NK cells, such as chimeric antigen receptor (CAR)-NK cells, dual antigen-targeting CAR NK cells, and adapter chimeric antigen receptor NK cells are considered to be an important tool for GBM immunotherapy. Therefore, this review describes the recent efforts of NK cell-based immunotherapy in GBM patients. We also describe key receptors expressing on NK cells such as killer cell immunoglobulin-like receptor, CD16, and natural killer group 2, member D (NKG2DL) receptor and discuss the function and importance of these molecules.
MEMBER ACCOUNT
登录成功会直接打开下一页。
